Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CASR | P41180 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3788323 | 0.96 | ADORA2A (0.50) | ADORA2AADORA1RAB9ALMNAADORA3 | |
| SCHEMBL3788321 | 0.96 | ADORA2A (0.50) | ADORA2AADORA1RAB9ALMNAADORA3 | |
| SCHEMBL1849285 | 0.94 | ADORA2A (0.55) | ADORA2AADORA1RAB9ALMNAADORA3 | |
| SCHEMBL1850220 | 0.94 | ADORA2A (0.55) | ADORA2AADORA1RAB9ALMNAADORA3 | |
| SCHEMBL23839858 | 0.93 | ADORA2A (0.56) | ADORA2AADORA1ADORA3CASR | |
| SCHEMBL1847715 | 0.93 | ADORA2A (0.56) | ADORA2AADORA1ADORA3CASR | |
| SCHEMBL1847597 | 0.93 | ADORA2A (0.56) | ADORA2AADORA1ADORA3CASR | |
| SCHEMBL21628114 | 0.93 | ADORA2A (0.56) | ADORA2AADORA1ADORA3CASR | |
| SCHEMBL1848773 | 0.93 | ADORA2A (0.56) | ADORA2AADORA1ADORA3CASR | |
| SCHEMBL23837276 | 0.93 | ADORA2A (0.56) | ADORA2AADORA1ADORA3CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311703-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311703-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 1/4885RAB9A 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.